Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
CryptoQuant Analyst: Bitcoin BPT Remains at a Moderate Level of 2.56, Caution Advised for Routine Pullback Risks Amid Uptrend

CryptoQuant Analyst: Bitcoin BPT Remains at a Moderate Level of 2.56, Caution Advised for Routine Pullback Risks Amid Uptrend

ChaincatcherChaincatcher2025/08/14 06:32
Show original

According to ChainCatcher, CryptoQuant analyst Axel Adler Jr tweeted that although Bitcoin's price has reached a new all-time high, the BPT indicator remains at a moderate level of 2.56, below the previous local high of 3.57.

At the same time, the Realized P&L Ratio is still at an average level, indicating that the current market risk is relatively low compared to previous overheated periods. From a technical perspective, the price remains above the 4-year moving average and its two standard deviations, confirming the continuation of the upward trend.

The analyst pointed out that caution is needed regarding the risk of regular pullbacks during the uptrend, and a BPT breakout above 3.0 could signal the market is entering a later stage.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Why did the Reserve Bank of Australia raise interest rates two weeks ago? Meeting minutes reveal inflation risks have become a reality, and waiting would be too costly

The Reserve Bank of Australia acknowledges that the trade-off between inflation and full employment has worsened, but maintains that its goal is to return the Consumer Price Index (CPI) to the 2-3% target range.

智通财经•2026/10/13 02:41

Three-year remission rate up to 94%! Johnson & Johnson (JNJ.US) Tremfya Crohn's disease study shows positive long-term results

Long-term data from two Phase 3 clinical trials by Johnson & Johnson show that adult Crohn's disease patients treated with Tremfya (guselkumab) achieved a clinical remission rate of up to 94% over three years.

智通财经•2026/10/13 01:56